Bullish JNJ COVID Vaccine development

١٩ سبتمبر ٢٠٢٠

JNJ has been aiding in developing their own covid vaccine and will have phase 2 FDA approval mid to end of September which can lead to positive growth overall in this strong company. TA shows that price is forming an ascending triangle which has a bullish sentiment and is projected to breakout around mid next year. Good potential LEAP or Holding of shares long term. (leaning toward LEAP slightly out of the money expiring Jan 21, 2022. 170c @ 460 a contract)